Category: Uncategorized

For laboratory research use only. The following is an educational summary of preclinical literature and is not intended for human or animal use, diagnosis, treatment, or any other application.

Selank and Semax are two synthetic heptapeptides that are frequently discussed together in the peptide-research literature because both emerged from the same Russian research program and both have been studied in the neuropeptide field. Despite that shared lineage, they derive from entirely different endogenous molecules and have been characterized around different mechanistic hypotheses in preclinical models. This article compares their origins and the mechanisms researchers have examined, without asserting any outcome as established fact.

Two different endogenous starting points

The most important distinction between these compounds is molecular: they are analogs of two unrelated regulatory peptides. Understanding that origin is the clearest way for researchers to keep the two straight.

Selank: a tuftsin analog

Selank is a synthetic analog of the endogenous immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg), extended with a Pro-Gly-Pro tail to slow enzymatic degradation. Its full sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Because tuftsin is associated with immune signaling, part of the preclinical interest in Selank has centered on where neuropeptide and immunomodulatory activity intersect. The single-compound material is described on the Selank product page.

Semax: an ACTH(4-10) analog

Semax is a synthetic analog of the ACTH(4-10) fragment of adrenocorticotropic hormone, comprising the ACTH(4-7) core (Met-Glu-His-Phe) with a Pro-Gly-Pro extension, giving the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It too originated in the Russian neuropeptide program. Unlike full ACTH, the fragment has been studied for reported activity that is characterized in the literature as distinct from classic corticotropic hormonal signaling, which is one reason it has been examined in nootropic and neuroprotective research contexts.

Side-by-side comparison

Mechanisms examined in preclinical research

Both peptides are short, so a recurring theme in the literature is how such small molecules could exert measurable central activity, and how their Pro-Gly-Pro extensions influence stability. The mechanistic hypotheses studied for each differ.

Selank in anxiolytic-focused models

Preclinical studies have examined Selank in rodent models of anxiety-like behavior. Reported mechanisms discussed in that literature include modulation of the GABAergic system, effects on the balance of monoamine neurotransmitters, changes in expression of brain-derived neurotrophic factor (BDNF), and inhibition of enkephalin-degrading enzymes, which has been proposed as one route by which the peptide is associated with altered signaling in these models. These are research observations in animal and in vitro systems and should not be read as effects in humans.

Semax in nootropic and neuroprotective models

Semax has been studied predominantly in cognition- and neuroprotection-oriented preclinical models, including models of cerebral ischemia. The mechanisms researchers have investigated include regulation of BDNF and nerve growth factor (NGF) expression in the hippocampus, modulation of dopaminergic and serotonergic systems, and effects on markers of oxidative and inflammatory response in injured tissue. As with Selank, these findings are described in preclinical literature and carry the usual limits of animal- and cell-model data.

Stability and the N-acetyl amidate analogs

A practical distinction researchers encounter is peptide stability. Both peptides are subject to enzymatic breakdown, and the literature includes chemically modified analogs designed to resist that degradation. N-terminal acetylation and C-terminal amidation are common strategies studied to extend a peptide’s half-life in experimental systems. The N-Acetyl Selank Amidate and N-Acetyl Semax Amidate materials reflect those modification strategies and are the forms many researchers select when stability in handling is a variable of interest.

The Selank–Semax blend in research settings

Because the two peptides have been studied around complementary themes — one more often in anxiolytic-type models, the other in nootropic and neuroprotective models — a combined preparation is sometimes used in research that examines both signaling directions in a single protocol. The Selank–Semax blend is provided for that purpose. Any experimental design combining two compounds should account for the fact that interaction effects in a blend are not simply the sum of each peptide’s individually reported activity, and remain an open research question.

Handling and characterization

As lyophilized peptides, both require reconstitution before use in laboratory work. Reconstitution is laboratory arithmetic relating solvent volume to the mass of peptide in the vial; the peptide reconstitution calculator handles that conversion. Researchers verifying identity and purity of a given lot can consult the batch documentation in the COA library.

References

• Kolomin T, Shadrina M, Slominsky P, Limborska S, Myasoedov N. A new generation of drugs: synthetic peptides based on natural regulatory peptides. Neuroscience and Medicine (review of the Russian regulatory-peptide program covering Selank and Semax origins).
• Zozulya AA, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic medication (Selank). Human Psychopharmacology, 2008 (clinical and mechanistic discussion of the tuftsin analog).
• Dolotov OV, et al. Semax, an analog of ACTH(4-10), regulates BDNF and trkB expression in the rat hippocampus. Brain Research / Journal of Neurochemistry (preclinical BDNF-expression study).
• Preclinical studies examining Selank effects on the GABAergic system, monoamine balance, and enkephalin degradation in rodent anxiety-like behavior models (Institute of Molecular Genetics, Russian Academy of Sciences).
• Preclinical studies examining Semax in cerebral ischemia and cognition models, including effects on NGF/BDNF expression and neuroprotective markers.

Citations above are described generically where a specific identifier could not be verified; readers should confirm each primary source directly in PubMed or the publishing journal before relying on it.

For laboratory research use only. Not for human or veterinary use. Nothing in this article is medical advice or a claim that any compound is safe or effective for any purpose.

The following is provided strictly for laboratory research and educational purposes; the compounds discussed are not for human or veterinary use, diagnosis, treatment, or consumption.

CJC-1295 and ipamorelin are two of the most frequently paired peptides in growth-hormone (GH) secretagogue research. They are often discussed together, yet they act on entirely different receptors and reach the pituitary somatotroph by distinct routes. This article compares the two as they appear in the preclinical literature, describes the mechanisms researchers have studied, and explains why investigators frequently examine them in combination in animal and in vitro models.

Two different receptors, one shared research target

Both peptides are studied for their influence on the release of endogenous growth hormone from the anterior pituitary, but they engage separate signaling pathways. Understanding that distinction is the key to understanding why they are commonly examined side by side.

CJC-1295: a GHRH analog

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH), based on the first 29 amino acids of the native peptide, GRF(1-29). It engages the GHRH receptor on somatotroph cells, the same receptor targeted by endogenous GHRH. Amino-acid substitutions in the sequence are described in the literature as improving resistance to enzymatic degradation relative to native GRF(1-29).

The compound is studied in two forms that Luxe Peptides catalogs separately. CJC-1295 with DAC incorporates a Drug Affinity Complex — a maleimidopropionyl group that binds covalently to circulating albumin in research models, a modification reported to substantially extend the molecule’s presence in plasma. CJC-1295 without DAC (frequently referred to in the literature as modified GRF 1-29) lacks that albumin-binding group and is characterized by a much shorter plasma presence. Teichman and colleagues reported that the DAC-bearing analog was associated with prolonged elevation of GH and insulin-like growth factor I (IGF-I) markers in a study of healthy adults, illustrating why the two forms are studied for different temporal profiles in research.

Ipamorelin: a selective GH secretagogue

Ipamorelin is a pentapeptide that acts as an agonist at the growth-hormone secretagogue receptor (GHS-R1a) — the ghrelin receptor — rather than the GHRH receptor. It belongs to the growth-hormone-releasing peptide (GHRP) family. In the foundational characterization by Raun and colleagues, ipamorelin was described as the first selective GH secretagogue: in the preclinical models studied, it stimulated GH release with little observed effect on adrenocorticotropic hormone (ACTH), cortisol, or prolactin markers, a selectivity profile that distinguished it from earlier peptides such as GHRP-6. That selectivity is a recurring reason it is chosen as a research tool.

Comparison at a glance

Why the two are frequently studied together

The most common reason researchers examine CJC-1295 and ipamorelin in combination is that they act on complementary pathways. A GHRH analog engages the GHRH receptor while a secretagogue engages the ghrelin receptor, and preclinical work dating back to the growth-hormone-releasing peptide studies of Bowers and colleagues has repeatedly observed that co-administration of a GHRH-type agonist with a GHRP-type secretagogue produces a larger GH pulse in research models than either class does alone. The two mechanisms are generally described as additive-to-synergistic: the GHRH pathway drives synthesis and release, while the ghrelin-receptor pathway is associated with amplifying the pulse and reducing inhibitory somatostatin signaling.

A second reason relates to the temporal profiles described above. Investigators studying pulsatile versus sustained signaling often pair a defined-duration secretagogue with either the short (no-DAC) or extended (DAC) form of the GHRH analog to model different release patterns. This is why a fixed-ratio research preparation such as the ipamorelin / CJC-1295 blend is a common format in the literature and in reference catalogs: it holds the ratio of the two mechanisms constant across a study.

It is worth stating plainly that the synergy described here is a characterization of hormone-release signaling in animal and in vitro research. It is not a statement about any human outcome, and no such outcome should be inferred from mechanistic data.

Handling and reconstitution in the laboratory

Both compounds are supplied as lyophilized powders that require reconstitution with a suitable solvent before use in a research setting. Determining the concentration of a reconstituted solution is straightforward laboratory arithmetic — the mass of peptide divided by the volume of solvent added. Researchers can work through that calculation with the peptide reconstitution calculator. Batch-specific purity and identity data for these compounds are published in the certificate-of-analysis (COA) library. None of this constitutes dosing guidance; it is concentration math for handling reference materials in the lab.

Summary

CJC-1295 is a GHRH analog studied for its action at the GHRH receptor, available in a short (no-DAC) and an albumin-extended (DAC) form. Ipamorelin is a selective ghrelin-receptor agonist studied for GH-release signaling with a reportedly clean cortisol and prolactin profile. Because they engage complementary receptors, they are frequently examined together in preclinical models, where combined stimulation has been observed to produce a larger GH pulse than either alone. All of the above describes receptor-level and cellular mechanisms in research contexts only.

References

• Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. PMID: 9849822.
• Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. PMID: 16352683.
• Bowers CY and colleagues have published extensively on the synergistic release of growth hormone when growth-hormone-releasing peptides are combined with GHRH in preclinical models; see the foundational GHRP characterization literature in endocrinology journals for primary reports.

Research use only. The compounds described are intended solely for in vitro and laboratory research by qualified professionals and are not for human or animal consumption, medical, cosmetic, or any therapeutic use.

The following is provided for research and educational purposes only. The compounds discussed are intended for laboratory research use only and are not for human or veterinary use, diagnosis, or treatment.

BPC-157 and TB-500 are two of the most frequently studied peptides in the preclinical tissue-repair literature, and they are often discussed together because both have been examined in models of connective-tissue, muscle, and vascular recovery. They are, however, mechanistically distinct molecules with different origins and different experimental profiles. This article compares what the preclinical literature reports about each, for researchers seeking to distinguish the two in an experimental design context.

What each compound is

BPC-157 (Body Protection Compound-157) is a synthetic, stable 15-amino-acid sequence derived from a partial fragment of a protein identified in gastric juice. Much of the foundational work characterizing it in animal models was conducted by Sikiric and colleagues over several decades. In research settings it is noted for stability in aqueous and gastric environments, which is why many rodent studies have examined both parenteral and oral administration routes.

TB-500 is a synthetic version of a fragment associated with thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide that is one of the principal actin-sequestering molecules in mammalian cells. Research literature on Tβ4 spans developmental biology, corneal and dermal wound-healing models, and cardiac injury models, with much of the mechanistic work associated with investigators such as Goldstein, Kleinman, and Sosne. “TB-500” in the research-chemical context generally refers to the synthetic active fragment studied for these actin-related properties.

Mechanisms studied in preclinical research

The clearest way to distinguish the two is by the cellular pathways researchers associate with each.

BPC-157: angiogenic and nitric-oxide-associated signaling

In preclinical models, BPC-157 has been studied in connection with the VEGFR2–Akt–eNOS pathway and with modulation of the nitric-oxide (NO) system. Animal-model studies have reported associations with vascular network formation (angiogenesis) and with growth-factor receptor expression in injured tissue. Researchers have also examined its interaction with the dopaminergic and serotonergic systems and with the gut–brain axis in rodent models. Because these findings derive largely from rat and mouse studies, they are best described as mechanistic observations rather than established outcomes.

TB-500 / Tβ4: actin regulation and cell migration

Thymosin beta-4’s best-characterized biochemical role is G-actin sequestration — binding monomeric actin and influencing the polymerization dynamics that underlie cell motility. In wound-healing and cardiac models, researchers have associated Tβ4 with cell migration, endothelial cell behavior, and modulation of inflammatory signaling. The distinction is important: where BPC-157 research emphasizes growth-factor and NO-linked angiogenic signaling, Tβ4 research centers on the cytoskeletal machinery that lets cells move into and remodel a site of injury.

Comparison at a glance

How the research contexts differ

Beyond mechanism, the two peptides occupy somewhat different corners of the literature. BPC-157 studies are almost entirely preclinical and concentrate on musculoskeletal and gastrointestinal injury models in rodents, frequently examining both systemic and local administration in animals. Thymosin beta-4, by contrast, has a broader biological literature because it is an endogenous molecule — it has been studied in developmental and regenerative biology and has been the subject of some human wound-healing investigation, though “TB-500” as sold for research is the synthetic fragment rather than the full clinical-grade parent peptide.

This distinction matters for experimental design. A researcher modeling angiogenesis or growth-factor-linked repair pathways is working in territory where BPC-157 has been more frequently characterized; a researcher studying cytoskeletal dynamics, cell migration, or actin biology is working where Tβ4 mechanisms are more directly relevant. The two are studied in overlapping injury models, which is why they are sometimes examined in combination in preclinical work.

The combination question

Because the two are associated with different pathways — angiogenic/NO signaling versus actin-driven cell migration — some preclinical discussions frame them as complementary axes of tissue-repair research rather than interchangeable compounds. Any combined use remains a research-model consideration only; there is no established human protocol, and the peptides should be treated strictly as laboratory reference materials.

Handling and characterization for research

Both are lyophilized peptides reconstituted with bacteriostatic or sterile water for laboratory work; reconstitution is straightforward laboratory arithmetic (concentration = mass of peptide ÷ volume of diluent). Researchers verifying identity and purity should review third-party analysis. Luxe Peptides publishes certificates of analysis in its COA library, and concentration math can be worked through with the peptide reconstitution calculator. Reference materials for the compounds discussed here are cataloged as BPC-157, TB-500 (thymosin beta-4), and a BPC-157 / TB-500 blend.

Summary

In the preclinical literature, BPC-157 is most often characterized through angiogenic and nitric-oxide-linked signaling in rodent musculoskeletal and gastrointestinal models, while TB-500 reflects the actin-sequestering, cell-migration biology of thymosin beta-4 studied in wound-healing and cardiac models. They are mechanistically distinct rather than substitutes, which is why they appear together in comparative and combination research discussions. All statements above describe observations in research models and should not be read as established effects in humans.

References

• Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: research on its cytoprotective and angiogenic properties in animal models. Current Pharmaceutical Design (review literature on BPC-157).
• Chang C-H, et al. Preclinical studies examining BPC-157 and tendon/fibroblast outcomes via VEGFR2-linked pathways in animal models.
• Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta-4: actin-sequestering protein moonlighting as a regenerative peptide — mechanistic reviews. Annals of the New York Academy of Sciences (thymosin beta-4 review series).
• Sosne G, et al. Preclinical corneal and dermal wound-healing studies of thymosin beta-4.
• Kleinman HK, Sosne G. Thymosin beta-4 in cell migration and tissue-repair research models.

Research use only. The compounds described are laboratory reference materials intended for in-vitro and preclinical research by qualified professionals. They are not drugs, supplements, or articles for human or veterinary use, and nothing here is medical advice or an instruction for administration.

The following is provided for laboratory research purposes only; Adamax is not a drug, supplement, or article intended for human or veterinary use.

Adamax is a synthetic peptide investigated in the laboratory as a chemically modified analog of Semax. In research nomenclature it is described as an adamantane-conjugated Semax derivative: the Semax heptapeptide backbone carrying an adamantane (tricyclic hydrocarbon) moiety. This article explains what Adamax is, how the adamantane modification distinguishes it from standard Semax and N-acetyl Semax, its origin in the adrenocorticotropic hormone (ACTH) fragment family, and how it has been framed in preclinical neuropeptide research. All discussion below concerns findings in research models, not outcomes in people.

What is Adamax?

Adamax is a Semax-class research peptide in which an adamantane group is attached to the Semax sequence. Semax itself is a short synthetic peptide, so Adamax is best understood as a structural variant designed by researchers to alter the physicochemical properties of the parent molecule — chiefly its lipophilicity and its resistance to enzymatic breakdown. Investigators studying the Semax family have used side-chain and terminal modifications (including acetylation, amidation, and lipophilic conjugation) as tools to probe how structure influences peptide stability and central-nervous-system activity in animal and in vitro systems. Adamax sits in this experimental lineage as the adamantane-modified member.

The ACTH(4-7) heptapeptide origin

To understand Adamax, it helps to start with Semax. Semax is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). Its N-terminal portion corresponds to the ACTH(4-7) fragment (Met-Glu-His-Phe) of adrenocorticotropic hormone, a fragment long studied for behavioral and neurotrophic activity that is independent of ACTH’s hormonal (corticosteroid-releasing) role. To that ACTH(4-7) core, researchers appended a C-terminal Pro-Gly-Pro tripeptide. This proline-rich terminus was introduced specifically to slow enzymatic degradation, since native ACTH fragments are rapidly cleaved by peptidases. The result — Semax — is a non-hormonal ACTH(4-10) analog that has been the subject of extensive preclinical neuropeptide research. Adamax and N-acetyl Semax are downstream modifications of this same scaffold.

The adamantane modification vs standard Semax and N-acetyl Semax

The three molecules share the ACTH(4-7)-derived heptapeptide core but differ in what is attached to it, and those differences are the whole point of the comparison in structure-activity research.

Adamantane is a rigid, cage-like saturated hydrocarbon (C₁₀H₁₆) widely used in medicinal-chemistry research as a lipophilic anchor. Conjugating it to a peptide markedly raises the molecule’s lipophilicity. In research contexts this modification is examined for two reasons: peptides bearing bulky hydrophobic groups can show altered resistance to proteolytic enzymes, and increased lipophilicity is a classic strategy investigated for improving passage across lipid membranes. Researchers therefore study Adamax as a probe of how a lipophilic conjugate changes the behavior of the Semax backbone relative to the acetylated/amidated (N-acetyl Semax) and unmodified variants. The comparison is a structure-activity question, not a claim that any variant is superior for any human purpose.

By contrast, N-acetyl Semax (including the amidate form) modifies only the peptide termini rather than adding a large hydrophobic cage. Acetylation of the N-terminus and amidation of the C-terminus are common peptide-stabilization strategies studied to reduce recognition by exopeptidases. Laboratories comparing N-acetyl Semax amidate with the adamantane-modified Adamax are essentially contrasting two different chemical philosophies applied to the same ACTH-derived core.

Preclinical nootropic and neurotrophic research framing

The scientific interest in the Semax family stems from work on ACTH(4-10)-derived peptides as putative neuromodulators. In preclinical and in vitro research, Semax and related analogs have been examined for their association with neurotrophic signaling — in particular studies reporting changes in brain-derived neurotrophic factor (BDNF) and its receptor TrkB, as well as nerve growth factor (NGF) expression, in rodent brain tissue and cultured cells. Researchers have also investigated the family in models of cerebral ischemia and oxidative stress, and in behavioral paradigms used to study learning and attention in animals. These are the reasons the Semax scaffold is frequently described in the literature as a “nootropic” or “neurotrophic” research peptide.

It is important to frame these findings precisely. The neurotrophic and behavioral observations reported for the Semax family come from animal models, cell culture, and limited experimental settings; they describe associations and mechanisms studied under controlled research conditions. Adamax specifically is a less extensively characterized derivative, and much of the mechanistic reasoning applied to it is extrapolated from the better-studied parent peptide and from the general chemistry of adamantane conjugation. Researchers evaluating Adamax typically treat it as a tool for probing how lipophilic modification affects the stability and central activity of an ACTH(4-7)-derived peptide, rather than as an established agent with defined effects.

Identity and purity documentation

Because Adamax is a modified analog rather than the parent peptide, identity confirmation matters when interpreting any result attributed to it: mass-spectrometric identity and HPLC purity data establish that the material under study is the adamantane-conjugated compound and not unmodified Semax or a partially cleaved species. Third-party certificates for our research materials are published in the COA library.

Summary

Adamax is an adamantane-conjugated derivative of Semax, itself a stabilized ACTH(4-7)-derived heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro). The adamantane group is a lipophilic modification studied to alter membrane permeability and metabolic stability, distinguishing Adamax from the terminally capped N-acetyl Semax amidate and from unmodified Semax. Within the neuropeptide literature the Semax family is studied for associations with neurotrophic signaling (BDNF, NGF) and for behavioral and neuroprotective endpoints in animal and in vitro models. Adamax is best understood as a research-grade structure-activity variant of that scaffold.

Reviewed for research accuracy

Reviewed for research accuracy on 2026-07-30. This article describes mechanisms studied in cell and animal models and does not represent clinical guidance.

References

• Preclinical studies have characterized Semax as a non-hormonal analog of the ACTH(4-10) fragment and described its Met-Glu-His-Phe-Pro-Gly-Pro sequence and enzymatic stability (peptide structure-activity literature on ACTH-derived neuropeptides).
• Research in rodent brain tissue and cell culture has examined Semax-associated changes in brain-derived neurotrophic factor (BDNF) and its TrkB receptor, and in nerve growth factor (NGF) expression (preclinical neurotrophic-signaling studies of the Semax family).
• Medicinal-chemistry research has described adamantane conjugation as a strategy for increasing peptide lipophilicity and metabolic stability (general adamantane structure-activity literature).
• Experimental studies have investigated Semax and related ACTH(4-10) analogs in models of cerebral ischemia, oxidative stress, and animal learning/attention paradigms (preclinical neuroprotection and behavioral literature).

Research use only. Adamax is sold strictly as a laboratory research chemical for in vitro and research-model study by qualified professionals. It is not a drug, food, cosmetic, or dietary supplement, and is not intended to diagnose, treat, cure, or prevent any disease or to be administered to humans or animals.

For laboratory and research use only. The compounds described here are not drugs, are not intended for human or veterinary use, and are not intended to diagnose, treat, cure, or prevent any condition.

“KLOW” is an informal name used across the research-peptide vertical for a multi-component blend built around peptides that appear frequently in tissue-repair and anti-inflammatory literature. Because the label is a vendor convention rather than a standardized formula, researchers comparing sources should confirm the exact composition of any given vial before designing an experiment. This guide describes each component’s studied mechanism and clarifies the most-searched point of confusion: which KLOW formulations include KPV and which do not.

What the KLOW blend is

KLOW refers to a co-formulated blend of short peptides and peptide fragments that have each been examined independently in models of wound healing, extracellular-matrix remodeling, and inflammation. The rationale sometimes offered in the literature for studying such peptides together is that they act through distinct, non-overlapping pathways — copper transport, cytoprotection, actin regulation, and melanocortin signaling — so researchers occasionally investigate them in combination to observe additive or independent effects in a single model. Combination data specific to KLOW as a fixed blend are limited; most of the published evidence concerns the individual components.

The KPV question: three-component vs. four-component KLOW

This is the distinction most researchers search for. Two naming conventions circulate:

• Three-component KLOW — GHK-Cu, BPC-157, and TB-500 only, with no KPV.
• Four-component KLOW — the three peptides above plus KPV, the C-terminal tripeptide of α-MSH.

Both are marketed under the same “KLOW” label, which is the source of the confusion. The Luxe Peptides KLOW blend is the four-component formulation: GHK-Cu, BPC-157, TB-500, and KPV together. Always verify the stated composition and the accompanying Certificate of Analysis against the specific catalog entry, since a blend labeled “KLOW” from another source may omit KPV entirely.

The four components at a glance

GHK-Cu (copper tripeptide-1)

GHK-Cu is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) that binds copper(II) with high affinity. In preclinical and in vitro research it has been associated with modulation of genes involved in extracellular-matrix synthesis and remodeling, and studies indicate it can influence collagen and glycosaminoglycan production in cultured fibroblasts. Reviews of the peptide have examined its role as a copper carrier and its observed effects on tissue-remodeling pathways in animal and cell models. As with all components here, human clinical data are limited and the mechanisms are described in a research context only. Researchers working with the copper complex should note its distinct handling and reconstitution characteristics relative to the other peptides in the blend.

BPC-157

BPC-157 is a synthetic 15-amino-acid sequence derived from a fragment of a gastric protein. Preclinical reviews have examined its cytoprotective profile and reported, in rodent models, associations with angiogenic signaling (including nitric-oxide and VEGF-related pathways) and with markers of connective-tissue and gastrointestinal-lining recovery after experimental injury. The evidence base is predominantly animal-model work; controlled human data are minimal. Effects should therefore be described strictly as observations within specific experimental systems rather than as established outcomes.

TB-500 (thymosin β4 fragment)

TB-500 is associated with the actin-binding region of thymosin β4, a naturally occurring peptide. Thymosin β4 is a well-characterized actin-sequestering protein, and research indicates it participates in cell migration, angiogenesis, and the cellular events involved in experimental wound closure. In animal wound-healing assays, thymosin β4 has been observed to accelerate the migration of keratinocytes and endothelial cells. Studies of the TB-500 fragment focus on this actin-regulatory mechanism in cell and animal models.

KPV

KPV is the C-terminal tripeptide (lysine-proline-valine) of α-melanocyte-stimulating hormone (α-MSH). In preclinical research it has been examined for anti-inflammatory activity that appears to be independent of the classical melanocortin-1 receptor pigmentation pathway. Cell and animal studies of intestinal inflammation have reported that KPV, taken up via the PepT1 transporter, is associated with reduced pro-inflammatory signaling (including NF-κB–linked pathways) in epithelial models. Its inclusion is precisely what distinguishes the four-component KLOW blend from the three-component version described above.

Reviewed for research accuracy

Reviewed for research accuracy on 2026-07-13. This article describes mechanisms studied in cell and animal models and does not represent clinical guidance.

References

• Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PMID: 29986520.
• Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969–988. PMID: 18644225.
• Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421–429. PMID: 16099219.
• Malinda KM, Sidhu GS, Mani H, et al. Thymosin β4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364–368. PMID: 10469335.
• Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. PMID: 18061177.
• Peer-reviewed preclinical reviews (Sikiric et al.) have examined the cytoprotective and angiogenic mechanisms attributed to BPC-157 in rodent injury models; readers should consult the primary literature directly, as controlled human data remain limited.

For laboratory and research use only. Not for human or veterinary use. Nothing here is medical advice, and no statement should be read as describing a therapeutic effect in humans.